CVAS-an interesting california-based biotech company here Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVAS-an interesting california-based biotech company here

CVAS 0.000400

0.0%

Oct 7 9:32 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (81)	4/23/2002 4:11:37 PM
From: nigel bates	Read Replies (1) of 126

Corvas Announces Findings of Preliminary Analyses Of Stroke Trial of UK-279,276 SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Corvas International, Inc. (Nasdaq: CVAS - news) announces that preliminary analyses of the multi-center Phase IIb study of UK-279,276 (formerly known as Neutrophil Inhibitory Factor, or rNIF) being conducted by Pfizer Inc (NYSE: PFE - news) have been completed. Full analysis of the comprehensive and complex dataset from this trial in acute stroke patients is ongoing. Decisions regarding the further development of UK-279,276 will be made upon completion of the full analysis. However, the results from the preliminary analyses of the data relating to the primary endpoint, which represent a small fraction of the predefined statistical analyses, do not support initiation of a Phase III study in stroke. The final results from this trial will be reported following complete data analysis and review, which the company hopes will be available mid-2002...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next